MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY

A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES

Róbert Gergely, I. Kovács, Miklós Schneider, Miklós Resch, András Papp, Zsuzsanna Récsán, Zoltán Zsolt Nagy, Mónika Ecsedy

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

PURPOSE:: To evaluate the macular thickness, choroidal thickness, and visual acuity changes in eyes of patients with bilateral chronic central serous chorioretinopathy during eplerenone treatment. METHODS:: This prospective clinical trial was conducted on patients with bilateral chronic central serous chorioretinopathy, who had subretinal fluid (SRF) in 1 eye. Twenty-eight patients were treated with 50 mg/day of oral eplerenone for 3 months and were observed for another 3 months. Twenty-eight eyes with SRF were compared with the 28 fellow eyes with pachychoroid pigment epitheliopathy. RESULTS:: The central macular and choroidal thickness showed a significant decrease (P < 0.005) at 3 months in all eyes, but change in choroidal thickness was smaller in nonexudative fellow eyes (P > 0.05 at 6 months). In the exudative eyes, the decrease in choroidal thickness showed a significant correlation with the resolution of SRF (P < 0.001). Visual acuity remained stable in all eyes, with significant improvement only in exudative eyes at 6 months (P < 0.005). Baseline choroidal thickness was a significant positive predictor for SRF decrease (P = 0.003). CONCLUSION:: Patients with chronic central serous chorioretinopathy can safely be treated with eplerenone as it can reverse choroidal vasodilation with an accompanying resolution of the SRF and improvement in visual acuity. These beneficial therapeutic effects are more pronounced in the exudative eyes.

Original languageEnglish
JournalRetina
DOIs
Publication statusAccepted/In press - Sep 13 2016

Fingerprint

Central Serous Chorioretinopathy
Mineralocorticoid Receptor Antagonists
Subretinal Fluid
Visual Acuity
Therapeutics
Therapeutic Uses
Vasodilation
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)
  • Ophthalmology

Cite this

MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY : A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES. / Gergely, Róbert; Kovács, I.; Schneider, Miklós; Resch, Miklós; Papp, András; Récsán, Zsuzsanna; Nagy, Zoltán Zsolt; Ecsedy, Mónika.

In: Retina, 13.09.2016.

Research output: Contribution to journalArticle

Gergely, Róbert ; Kovács, I. ; Schneider, Miklós ; Resch, Miklós ; Papp, András ; Récsán, Zsuzsanna ; Nagy, Zoltán Zsolt ; Ecsedy, Mónika. / MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY : A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES. In: Retina. 2016.
@article{1def86f47b914b0d89ced27585741859,
title = "MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES",
abstract = "PURPOSE:: To evaluate the macular thickness, choroidal thickness, and visual acuity changes in eyes of patients with bilateral chronic central serous chorioretinopathy during eplerenone treatment. METHODS:: This prospective clinical trial was conducted on patients with bilateral chronic central serous chorioretinopathy, who had subretinal fluid (SRF) in 1 eye. Twenty-eight patients were treated with 50 mg/day of oral eplerenone for 3 months and were observed for another 3 months. Twenty-eight eyes with SRF were compared with the 28 fellow eyes with pachychoroid pigment epitheliopathy. RESULTS:: The central macular and choroidal thickness showed a significant decrease (P < 0.005) at 3 months in all eyes, but change in choroidal thickness was smaller in nonexudative fellow eyes (P > 0.05 at 6 months). In the exudative eyes, the decrease in choroidal thickness showed a significant correlation with the resolution of SRF (P < 0.001). Visual acuity remained stable in all eyes, with significant improvement only in exudative eyes at 6 months (P < 0.005). Baseline choroidal thickness was a significant positive predictor for SRF decrease (P = 0.003). CONCLUSION:: Patients with chronic central serous chorioretinopathy can safely be treated with eplerenone as it can reverse choroidal vasodilation with an accompanying resolution of the SRF and improvement in visual acuity. These beneficial therapeutic effects are more pronounced in the exudative eyes.",
author = "R{\'o}bert Gergely and I. Kov{\'a}cs and Mikl{\'o}s Schneider and Mikl{\'o}s Resch and Andr{\'a}s Papp and Zsuzsanna R{\'e}cs{\'a}n and Nagy, {Zolt{\'a}n Zsolt} and M{\'o}nika Ecsedy",
year = "2016",
month = "9",
day = "13",
doi = "10.1097/IAE.0000000000001303",
language = "English",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY

T2 - A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES

AU - Gergely, Róbert

AU - Kovács, I.

AU - Schneider, Miklós

AU - Resch, Miklós

AU - Papp, András

AU - Récsán, Zsuzsanna

AU - Nagy, Zoltán Zsolt

AU - Ecsedy, Mónika

PY - 2016/9/13

Y1 - 2016/9/13

N2 - PURPOSE:: To evaluate the macular thickness, choroidal thickness, and visual acuity changes in eyes of patients with bilateral chronic central serous chorioretinopathy during eplerenone treatment. METHODS:: This prospective clinical trial was conducted on patients with bilateral chronic central serous chorioretinopathy, who had subretinal fluid (SRF) in 1 eye. Twenty-eight patients were treated with 50 mg/day of oral eplerenone for 3 months and were observed for another 3 months. Twenty-eight eyes with SRF were compared with the 28 fellow eyes with pachychoroid pigment epitheliopathy. RESULTS:: The central macular and choroidal thickness showed a significant decrease (P < 0.005) at 3 months in all eyes, but change in choroidal thickness was smaller in nonexudative fellow eyes (P > 0.05 at 6 months). In the exudative eyes, the decrease in choroidal thickness showed a significant correlation with the resolution of SRF (P < 0.001). Visual acuity remained stable in all eyes, with significant improvement only in exudative eyes at 6 months (P < 0.005). Baseline choroidal thickness was a significant positive predictor for SRF decrease (P = 0.003). CONCLUSION:: Patients with chronic central serous chorioretinopathy can safely be treated with eplerenone as it can reverse choroidal vasodilation with an accompanying resolution of the SRF and improvement in visual acuity. These beneficial therapeutic effects are more pronounced in the exudative eyes.

AB - PURPOSE:: To evaluate the macular thickness, choroidal thickness, and visual acuity changes in eyes of patients with bilateral chronic central serous chorioretinopathy during eplerenone treatment. METHODS:: This prospective clinical trial was conducted on patients with bilateral chronic central serous chorioretinopathy, who had subretinal fluid (SRF) in 1 eye. Twenty-eight patients were treated with 50 mg/day of oral eplerenone for 3 months and were observed for another 3 months. Twenty-eight eyes with SRF were compared with the 28 fellow eyes with pachychoroid pigment epitheliopathy. RESULTS:: The central macular and choroidal thickness showed a significant decrease (P < 0.005) at 3 months in all eyes, but change in choroidal thickness was smaller in nonexudative fellow eyes (P > 0.05 at 6 months). In the exudative eyes, the decrease in choroidal thickness showed a significant correlation with the resolution of SRF (P < 0.001). Visual acuity remained stable in all eyes, with significant improvement only in exudative eyes at 6 months (P < 0.005). Baseline choroidal thickness was a significant positive predictor for SRF decrease (P = 0.003). CONCLUSION:: Patients with chronic central serous chorioretinopathy can safely be treated with eplerenone as it can reverse choroidal vasodilation with an accompanying resolution of the SRF and improvement in visual acuity. These beneficial therapeutic effects are more pronounced in the exudative eyes.

UR - http://www.scopus.com/inward/record.url?scp=84987625004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987625004&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000001303

DO - 10.1097/IAE.0000000000001303

M3 - Article

JO - Retina

JF - Retina

SN - 0275-004X

ER -